Sekucinumab injection for erythrodermic psoriasis
Part of Skin clinical trials.
This trial tests if Sekucinumab injections can help people with erythrodermic psoriasis, a severe type of psoriasis that causes redness, swelling, and scaling over most of the body. It aims to reduce symptoms and improve skin condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with erythrodermic psoriasis, meaning red, inflamed, scaly skin covering more than 90% of your body.
- You are not pregnant or breastfeeding.
- You do not have diabetes or a weakened immune system.
- You have not used biologic medicines for another condition besides erythrodermic psoriasis.
- You are not allergic to the study drug (Sekucinumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study looks at how well a psoriasis medicine called secukinumab works, and what happens when treatment is stopped in people with moderate-to-severe plaque psoriasis. It may help show the best way to manage symptoms and prevent flare-ups.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This trial compares ixekizumab and secukinumab to see which works better for people over 70 with plaque psoriasis. It aims to find a safer and more effective treatment for older adults.
This study tests a new injection called SHR-1139 for people with moderate-to-severe plaque psoriasis. The goal is to see if it can safely improve your skin condition.
This study tests a new injectable medicine for people with moderate-to-severe plaque psoriasis. It aims to see if it is safe and effective at reducing symptoms like redness and scaling.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
Hear when a new Erythrodermic Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.